Edonia raises €15M to scale microalgae protein for the food industry

Edonia (Agen, Nouvelle-Aquitaine) has raised €15 million to scale its microalgae-based protein ingredient business for food manufacturers. The round was led by SWEN Blue Ocean 2 (SWEN Capital Partners' ocean-economy fund), with Asterion Ventures, EIT Food, and Bpifrance participating. The stage is unstated; the company was founded in 2023 by Hugo Valentin (CEO). Note: Maddyness reported €12M; EU-Startups, Tech.eu, and EIT Food's press release all confirm €15M — this article uses the figure corroborated by three independent sources.

The protein gap microalgae fills

Soy dominates global protein ingredient supply — and carries the liabilities that go with it: deforestation exposure, a long supply chain, and a single-source concentration risk that commodity markets regularly remind food manufacturers about. Animal protein faces the opposite problem: supply is resilient but regulatory and consumer pressure around emissions and welfare is intensifying. Insect protein, despite early European enthusiasm, has not scaled commercially.

Microalgae protein arrives into this gap with a distinct profile. It grows in controlled aquatic environments with no arable land requirement, can be sited near industrial users to shorten supply chains, produces complete protein at high yields, and carries a clean sustainability narrative that food manufacturers can integrate into ingredient sourcing commitments. Edonia's B2B model — selling protein ingredients to manufacturers rather than building consumer-facing products — positions it to supply into existing formulations without triggering the consumer-acceptance friction that has slowed other alternative proteins.

The investors and what they signal

SWEN Blue Ocean 2's lead is a portfolio-logic play: SWEN Capital Partners backed Syntetica (nylon recycling, Cleantech / Textiles) in July 2026, and microalgae is a natural extension of SWEN's ocean-economy and sustainability thesis. EIT Food's equity participation — rather than the grants that define most of its early-stage involvement — signals that Edonia has moved past the R&D phase and into commercial traction that justifies investor exposure.

Bpifrance's presence is standard infrastructure for French agri-food companies at this size; Asterion Ventures adds mid-stage expertise. "Nos microalgues offrent une source protéique durable, locale et à haute valeur nutritionnelle pour l'industrie agroalimentaire," said Valentin.

Scale is the unanswered question

The €15M funds two parallel tracks: production capacity expansion (more biomass per cycle, more processing throughput) and R&D on new microalgae strains optimised for specific protein profiles and functional properties. Both are necessary — but the commercial test is simpler: can Edonia deliver consistent protein ingredients at a cost and specification that food manufacturers can build into their formulations? Microalgae protein's biological properties are not in doubt; its cost curve at industrial scale, and its organoleptic compatibility with existing food matrices, are the engineering problems that will determine whether this stays a specialty ingredient or scales to a commodity substitute.